# EDGAR Filing Document

**Accession Number:** 0001770069
**File Stem:** 0000000000-25-008433
**Filing Date:** 2025-8
**Character Count:** 5358
**Document Hash:** 6e9f0c7b30f2eaca7320896183d4e3d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008433.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0000000000-25-008433

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250812

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MapLight Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001770069
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832163243
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-07130

**BUSINESS ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-839-4360

**MAIL ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvarado Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190307
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950123-24-002827

## Text-Extract

```

                                                            August 12, 2025

Christopher Kroeger, M.D.
Chief Executive Officer
MapLight Therapeutics, Inc.
800 Chesapeake Drive
Redwood City, CA 94063

       Re: MapLight Therapeutics, Inc.
           Amendment No. 3 to Draft Registration Statement on Form S-1
           Submitted July 30, 2025
           CIK No. 0001770069
Dear Christopher Kroeger M.D.:

     We have reviewed your amended draft registration statement and have the
following
comments.

        Please respond to this letter by providing the requested information
and either
submitting an amended draft registration statement or publicly filing your
registration
statement and non-public draft submissions on EDGAR. If you do not believe a
comment
applies to your facts and circumstances or do not believe an amendment is
appropriate, please
tell us why in your response.

       After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments. Unless we note otherwise, any references to prior comments are to
comments in
our April 24, 2024, letter.

Registration Statement on Form S-1 filed July 30, 2025
Prospectus Summary
Overview, page 1

1.
       We note your disclosure that, based on the results of your recent Phase
1 Study 013,
       you believe ML-007C-MA has the potential to be a "differentiated M1/M4
muscarinic
       agonist with enhanced tolerability, improved ease of use and
comprehensive symptom
       improvement." Please provide the basis for your belief that ML-007C-MA
will result
       in "comprehensive symptom improvement" or otherwise advise. Your
disclosure
       should present objective information about trial results, rather than
conclusions as to
 August 12, 2025
Page 2

       the safety or efficacy of your product candidates. Please revise this
statement, and any
       others like it, to remove the conclusions or implications that your
product candidates
       will be safe and effective, as such conclusions are within the sole
authority of the
       FDA and comparable foreign regulators.

2.     We note your disclosure here and on page 100 that there was a "recent
FDA approval
       of an M1/M4 muscarinic agonist paired with a peripherally restricted
muscarinic
       antagonist...for the treatment of schizophrenia." Please revise your
disclosure to
       identify the recent approval you are referencing or otherwise advise.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Contractual Obligations, page 95

3.     We note your disclosure regarding certain grant agreements with the
Michael J. Fox
       Foundation and "license and collaboration agreements with NeuroSolis,
Stanford
       University, Vanderbilt University and other universities" on page 95.
Please disclose
       the material terms of these agreements and file them as exhibits
pursuant to Item
       601(b)(10) of Regulation S-K, or provide an analysis supporting your
determination
       that the agreements are not material.
General

4.     We note your disclosure on page F-29 that Catalyst4, Inc. owns
approximately 55.4%
       of the company's outstanding shares as of December 31, 2024. If the
company will be
       a "controlled company" within the meaning of Nasdaq's rules after the
offering, please
       revise your disclosure to make this clear and explain the implications
thereof. If
       Catalyst4, Inc. will not own more than 50% of the voting power after the
offering,
       please clarify.
        Please contact Gary Newberry at 202-551-3761 or Vanessa Robertson at
202-551-
3649 if you have questions regarding comments on the financial statements and
related
matters. Please contact Jason Drory at 202-551-8342 or Laura Crotty at
202-551-7614 with
any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Mark Ballantyne

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._